UY38266A - Piridinil y pirazinil-(aza) indolsulfonamidas - Google Patents

Piridinil y pirazinil-(aza) indolsulfonamidas

Info

Publication number
UY38266A
UY38266A UY0001038266A UY38266A UY38266A UY 38266 A UY38266 A UY 38266A UY 0001038266 A UY0001038266 A UY 0001038266A UY 38266 A UY38266 A UY 38266A UY 38266 A UY38266 A UY 38266A
Authority
UY
Uruguay
Prior art keywords
aza
pyrazinil
indolsulfonamides
pyridinil
gpr17
Prior art date
Application number
UY0001038266A
Other languages
English (en)
Inventor
Christa E Mueller
Cécile Pegurier
Ali El-Tayeb
Joerg Hockemeyer
Marie Ledecq
Laurent Provins
Alvaro Cardenas
Nader Boshta
Mahmoud Rashed
Original Assignee
Ucb Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Gmbh filed Critical Ucb Pharma Gmbh
Publication of UY38266A publication Critical patent/UY38266A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a piridinil y pirazinil-(aza) indolsulfonamidas que tienen actividad moduladora de GPR17. Los compuestos tienen utilidad en el tratamiento de una variedad de trastornos asociados con GPR17.
UY0001038266A 2018-06-19 2019-06-18 Piridinil y pirazinil-(aza) indolsulfonamidas UY38266A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18178429 2018-06-19
EP19157936 2019-02-19

Publications (1)

Publication Number Publication Date
UY38266A true UY38266A (es) 2020-01-31

Family

ID=67070797

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038266A UY38266A (es) 2018-06-19 2019-06-18 Piridinil y pirazinil-(aza) indolsulfonamidas

Country Status (24)

Country Link
US (1) US11939319B2 (es)
EP (2) EP4074703B1 (es)
JP (1) JP7382973B2 (es)
KR (1) KR20210022675A (es)
CN (1) CN112469710B (es)
AU (1) AU2019289788A1 (es)
BR (1) BR112020025618A2 (es)
CA (1) CA3100795A1 (es)
CL (1) CL2020003202A1 (es)
DK (2) DK4074703T3 (es)
ES (2) ES2972491T3 (es)
FI (1) FI4074703T3 (es)
HR (2) HRP20240071T1 (es)
HU (2) HUE060128T2 (es)
IL (1) IL279428B2 (es)
LT (2) LT4074703T (es)
MX (1) MX2020012173A (es)
PL (2) PL3810591T3 (es)
RS (2) RS65272B1 (es)
SG (1) SG11202012421TA (es)
SI (1) SI4074703T1 (es)
TW (1) TW202016088A (es)
UY (1) UY38266A (es)
WO (1) WO2019243303A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020254289A1 (en) 2019-06-17 2020-12-24 Ucb Pharma Gmbh N-(phenyl)-indole-3-sulfonamide derivatives and related compounds as gpr17 modulators for treating cns disorders such as multiple sclerosis
CN112375027B (zh) * 2020-12-07 2023-03-31 中国药科大学 吲哚磺酰胺类衍生物及其医药用途
CN117794898A (zh) * 2021-06-04 2024-03-29 瑞文德医疗公众有限公司 3-吡咯基磺酰胺化合物作为gpr17拮抗剂
WO2024017863A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel pyrimidinyl and triazinyl sulfonamide derivatives
WO2024017858A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel naphthyl and isoquinoline sulfonamide derivatives
WO2024017855A1 (en) * 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isothiazol-3-yl and isoxazol-3-yl sulfonamide compounds
WO2024017857A1 (en) * 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel imidazopyridine and pyrazolopyridine sulfonamide derivatives
WO2024017856A1 (en) 2022-07-20 2024-01-25 F. Hoffmann-La Roche Ag Novel isoquinolinone, pyrrolopyridinone and thienopyridinone sulfonamide derivatives
WO2024042147A2 (en) * 2022-08-26 2024-02-29 F. Hoffmann-La Roche Ag Novel deuterated pyrimidin-2-yl sulfonamide derivatives
WO2024104462A1 (en) * 2022-11-20 2024-05-23 Myrobalan Therapeutics Nanjing Co. Ltd Gpr17 modulators and uses thereof
WO2024115733A1 (en) * 2022-12-02 2024-06-06 Rewind Therapeutics Nv Fused pyrrolyl-sulfonamide compounds

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9702680D0 (sv) 1997-07-11 1997-07-11 Astra Pharma Prod New formulation
DE19814084B4 (de) 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
SE9904750D0 (sv) 1999-12-23 1999-12-23 Pharmacia & Upjohn Ab New formulation, use and method
JP4685767B2 (ja) 2004-04-27 2011-05-18 武田薬品工業株式会社 Ｇタンパク質共役型レセプタータンパク質の新規リガンドとその用途
ITMI20042007A1 (it) * 2004-10-21 2005-01-21 Consiglio Nazionale Ricerche "modulatori del ricettore gpr17 e loro impieghi terapeutici"
JP5225100B2 (ja) 2005-12-20 2013-07-03 テイコク ファーマ ユーエスエー インコーポレーテッド インドールセロトニン受容体作動薬の経皮投与方法及びそれを使用するための経皮組成物
WO2009000262A1 (de) 2007-06-25 2008-12-31 Acino Ag Elektrophoretisches transdermales applikationssystem
WO2011113032A2 (en) 2010-03-11 2011-09-15 Swinford Jerry L Method and apparatus for washing dowhole tubulars and equipment
IT1402549B1 (it) * 2010-11-03 2013-09-13 Univ Pisa Composti e composizioni che modulano gpr17 e loro usi terapeutici e diagnostici
EP2567698B1 (en) 2011-09-07 2014-02-12 Rheinische Friedrich-Wilhelms-Universität Bonn GPR 17 agonists and screening assay
WO2013167177A1 (en) 2012-05-09 2013-11-14 Universita' Degli Studi Di Milano Gpr17 receptor modulators.
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類

Also Published As

Publication number Publication date
HRP20221290T1 (hr) 2022-12-23
RS63760B1 (sr) 2022-12-30
ES2972491T3 (es) 2024-06-13
HUE065411T2 (hu) 2024-05-28
IL279428B2 (en) 2024-03-01
DK4074703T3 (da) 2024-01-29
EP4074703A1 (en) 2022-10-19
MX2020012173A (es) 2021-01-29
RS65272B1 (sr) 2024-03-29
HUE060128T2 (hu) 2023-01-28
EP3810591A1 (en) 2021-04-28
JP7382973B2 (ja) 2023-11-17
LT3810591T (lt) 2022-11-25
PL3810591T3 (pl) 2022-12-19
CN112469710B (zh) 2024-05-14
PL4074703T3 (pl) 2024-05-13
CN112469710A (zh) 2021-03-09
WO2019243303A1 (en) 2019-12-26
IL279428A (en) 2021-01-31
SG11202012421TA (en) 2021-01-28
US11939319B2 (en) 2024-03-26
JP2021527690A (ja) 2021-10-14
DK3810591T3 (da) 2022-10-31
EP4074703B1 (en) 2023-11-29
ES2929992T3 (es) 2022-12-05
SI4074703T1 (sl) 2024-03-29
HRP20240071T1 (hr) 2024-03-29
CL2020003202A1 (es) 2021-05-07
KR20210022675A (ko) 2021-03-03
FI4074703T3 (fi) 2024-02-01
LT4074703T (lt) 2024-02-26
CA3100795A1 (en) 2019-12-26
TW202016088A (zh) 2020-05-01
AU2019289788A1 (en) 2021-01-21
US20210206749A1 (en) 2021-07-08
IL279428B1 (en) 2023-11-01
BR112020025618A2 (pt) 2021-03-23
EP3810591B1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
CL2020003202A1 (es) Piridinil y pirazinil-(aza)indolsulfonamidas
CO2019007298A2 (es) Inhibidores de tgfβ1 isoforma-específicos contexto-permisivos y uso de los mismos
PH12020551397A1 (en) Cot modulators and methods of use thereof
CL2019001660A1 (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas.
CL2016002516A1 (es) “compuestos derivados de espirociclo sustituidos, inhibidores atx; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, inflamaciones, dolor neuropático, enfermedades fibróticas, trombosis, entre otros”. pct
CL2017001464A1 (es) Modulación inmunológica
CL2018002334A1 (es) Moduladores de complementos factor b (divisional solicitud 201600606)
CO2017001994A2 (es) Compuestos activos hacia bromodominios
EA201790737A1 (ru) Комбинированная терапия
UY36032A (es) Moléculas de anticuerpo que se unen a lag-3 y usos de las mismas
MX2020012823A (es) Alcoxipiridinil indolsulfonamidas sustituidas.
EA201891607A1 (ru) Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований
EA201500934A1 (ru) Кардио- и нефропротективная противодиабетическая терапия
PH12015502161A1 (en) Therapeutic compounds and compositions
TR201903840T4 (tr) İnsan tamamlayıcı C5'e bağlanan polipeptitler.
EA201692204A1 (ru) Композиции и способы модулирования экспрессии фактора комплемента b
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
BR112017008481A2 (pt) composto antimicótico
CO2019011265A2 (es) Moduladores de la expresión de pcsk9
MX2021013354A (es) Metodos para tratar y/o prevenir queratosis actinica.
CL2020000056A1 (es) Nuevos derivados de xantina sustituidos.
EA202191342A1 (ru) Модуляторы экспрессии irf5
EA201791819A1 (ru) Комбинированная терапия с применением конъюгата антитела против cd19 с лекарственным средством и винкристина
CL2016001428A1 (es) Uso de una composicion con ejercicios cognitivos util para la prevencion o el tratamiento de un desarrollo cognitivo retrasado en los niños.
TR201905218T4 (tr) Nörodejenerati̇f hastaliklarin tedavi̇si̇ i̇çi̇n yararli vi̇tanoli̇dler.

Legal Events

Date Code Title Description
104 Application deemed to be withdrawn (no substantive examination fee paid)

Effective date: 20201203